Description
Risk factors, diagnosis and management of (azole-resistant) invasive aspergillosis
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: Risk factors, diagnosis and management of (azole-resistant) invasive aspergillosis
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart
